The Epoch Times is an independent voice in print and on the web. We report news responsibly and truthfully so that readers can improve their own lives and increase their understanding and respect for their neighbors next door and around the globe. In our approach and in our content, we uphold universal human values, rights, and freedoms. We are a business that puts our readers’ interests first, in all that we do.
Who We Are
Epoch Times is a privately held news media company. Our network of local reporters throughout the world uncovers stories that are authentically local, yet also globally relevant. Our independence enables us to report widely and present a diversity of opinions.
During a time when the world is changing ever more quickly, people need reliable information to understand events and trends. We strive to make a positive impact on people’s lives by helping all people understand the world and themselves, and to respect and appreciate each other. We report stories and air opinions unavailable elsewhere.
A special strength of The Epoch Times is our coverage of China. Today the world is increasingly looking to China, as this troubled giant goes through tremendous changes. Business and political leaders, and also world citizens, want to understand better what is happening there. We are able to provide well-sourced stories that no one else has through the original reporting done by the Chinese-language edition of The Epoch Times.
Andy Hecht is a sought-after commodity and futures trader, an options expert and analyst. He is the #2 ranked author on Seeking Alpha in both the commodities and precious metals categories. He is also the author of the weekly Hecht Commodity Report on Marketplace - the most comprehensive, deep-dive commodities report available on Seeking Alpha.
Andy spent nearly 35 years on Wall Street, including two decades on the trading desk of Phillip Brothers, which became Salomon Brothers and ultimately part of Citigroup.
Over the past two decades, he has researched, structured and executed some of the largest trades ever made, involving massive quantities of precious metals and bulk commodities.
Andy understands the market in a way many traders can’t imagine. He’s booked vessels, armored cars, and trains to transport and store a broad range of commodities. And he’s worked directly with The United Nations and the legendary trading group Phibro.
Today, Andy remains in close contact with sources around the world and his network of traders.
“I have a vast Rolodex of information in my head… so many bull and bear markets. When something happens, I don’t have to think. I just react. History does tend to repeat itself over and over.”
His friends and mentors include highly regarded energy and precious metals traders, supply line specialists and international shipping companies that give him vast insight into the market.
Andy’s writing and analysis are on many market-based websites including CQG. Andy lectures at colleges and Universities. He also contributes to Traders Magazine. He consults for companies involved in producing and consuming commodities. Andy's biweekly radio show, The Commodities Hour with Andy Hecht, can be heard on Tuesdays and Thursdays from 5-6 PM EST on www.tfnn.com. Andy’s first book How to Make Money with Commodities, published by McGraw-Hill was released in 2013 and has received excellent reviews. Andy held a Series 3 and Series 30 license from the National Futures Association and a collaborator and strategist with hedge funds. Andy is the commodity expert for the website about.com and blogs on his own site technomentals.com.
Trader of equities and options for over 12 years. Proprietary trading strategy involving options and biotech with a very high win to loss ratio. SMID cap biotech. Passionate about science and cooking.
"Win or lose, everybody gets what they want out of the market. Some people seem to like to lose, so they win by losing money."
I am an analyst and CFA Charterholder that gained experience in the investment industry through positions as a proprietary trader and a portfolio management administrator. I began contributing to Seeking Alpha as a way to share my thoughts on the biopharmaceutical industry. I discussed ways to minimize risk in biopharmaceutical investing through conservative pipeline valuation and balance sheet analysis to identify companies presenting a compelling valuation to potential investors. I also touched on ways to apply knowledge of the markets to improve personal finance. My pieces included either stock-specific analysis or general biopharmaceutical investing discussion through my Biotech Weekly blog. My research appeared on the websites of CNBC, Seeking Alpha, Reuters, Google Finance, Morningstar, NASDAQ, and MarketWatch.
Note: Articles and comments are my own opinions, are not related to the opinions of my employer, and should not be considered investment advice. Make sure to do your own due diligence before making an investment decision. Thanks!
I focus on the microcap space (market cap below $250 million) because it is one of the most inefficient and "alpha rich" areas of the global equity market, which provides the greatest opportunity to generate alpha through fundamental research.
I use a bottom up, investment decision making process. The ideal investment has an asymmetric risk/return profile with a limited downside (e.g. high net cash balance, strong cash flow) and significant upside (e.g. asset value extraction, overlooked business model transition).
Microcaps are particularly attractive to the following groups:
Activist investors. A small absolute investment (on a dollar basis) can be leveraged into a relatively large position (as a percentage of shares outstanding), which provides a greater ability to demand change.
Private equity firms. The persistent microcap discount can be “arbed away” via an LBO with the new owners accruing all of the gains for themselves. The small absolute size of many microcaps on an EV basis significantly expands the number of firms able to pursue this strategy.
This inefficiency exists for several reasons.
A lack of analyst coverage due to lower trading volume (less soft dollars from HF/MF), the global settlement that permanently severed the link between research/banking and the rise in electronic trading/decimalization. Moreover, none of these trends are likely to reverse for the foreseeable future (if ever).
A lack of institutional products given the natural capacity constraint for new/existing managers.
An inability to effectively implement a passive approach (e.g. ETFs, index funds) due to the lower liquidity and wider bid/ask spread. However, each of these obstacles can be overcome by using a combination of electronic trading tools (e.g. algos) and patience in building a positive size.
Inaccurate and persistent misconceptions about microcaps (e.g. they are riskier than larger cap stocks).
I currently trade for my personal account but would like to move into the investment management side of the industry.
Arrow Loop Research delivers a value-based investing newsletter called Arrow Loop Research's Actionable Ideas for Maximizing Returns. Sign up for a free trial here. Arrow Loop Research provides general investment advice. Nothing contained in the newsletter should be construed as specific investment advice.
Dr. Paul Price, writer of Arrow Loop Research's premium research service, writes about stocks, options and the market every weekday on Real Money Pro, a subscription site on TheStreet.com. Paul has been a speaker at the International Traders Expo in New York City and the Options and Forex Expo in Las Vegas. He also gives investment seminars for subscribers of TheStreet's multiple subscription sites. Dr. Price is a featured contributor on Market Shadows.com, GuruFocus.com and TalkMarkets.com.
Paul followed his passion for the stock market when he gave up his career as a dentist to join Merrill Lynch back in April of 1987. Paul feels that he is “living the dream” of many investors. He stopped “going to work” when he turned 50 (in the year 2000) and has been living well from his investment returns ever since.
Paul enjoys sharing the accumulated market wisdom he’s gained from years in the markets. He loves analyzing companies and picking individual stocks. According to Paul, once you know what equities to buy, option writing (selling covered calls and/or naked puts) just flows naturally. They serve as ways to impose investment discipline and create income while providing an extra margin of safety versus plain vanilla share ownership. Paul’s articles stand out for their unique graphics which are packed with information which distills our TMI (too much information) world into easy to understand, and actionable advice.
Mr. Binkley is the managing director of Binkley Wealth Management Group LLC, a fee-only, independent Registered Investment Adviser located in Avon, Indiana.
Mr. Binkley has been an Investment Adviser Representative since 1993. In 2010, he formed Binkley Wealth Management Group as a wealth education and management firm dedicated to value-added and personalized client service as well as unbiased asset management, financial planning, and investment counsel.
Binkely Wealth Management Group partners with clients to help them manage their portfolios under an AUM fee through the client’s own accounts at Scottrade. The firm also provides investment counsel and coaching to self-directed investors on an hourly fee basis.
Our custodian Scottrade may charge a commission to buy or sell an investment. We are not employees of Scottrade and receive no compensation from them for placing trades through them. We charge no commissions. No Commissions. No Conflicts. Unbiased advice.
IMPORTANT DISCLOSURES The opinions and or strategies voiced in any of our articles are for general information only and are not intended to provide specific advice or recommendations for any individual. To determine which strategies or investment(s) may be appropriate for you, consult your financial advisor prior to investing. Any performance referenced is historical and is no guarantee of future results. Any indices mentioned are unmanaged and cannot be invested into directly.
Before making any investment you should seek counsel from a qualified advisor whom you trust. All investments have risk including loss of principal. Past performance does not guarantee future results.
Nicholas Marshi is the Editor of the BDC Reporter (www.bdcreporter.com), the leading online publication dedicated to the Business Development Company ("BDC") sector. The BDC Reporter is read by thousands of individual and institutional investors for its broad and incisive coverage of this $60bn segment of the financial sector. Since 2008, Mr Marshi has also been a frequent contributor to Seeking Alpha, penning hundreds of articles and blog posts. Mr Marshi is also the Chief Investment Officer of Southland Capital Management (SCM), a Registered Investment Adviser based in Los Angeles, California. SCM manages investment portfolios, both for its own account and those of third parties, solely in the publicly traded securities of BDCs. Since 2009 SCM has also managed a "friends and family" investment fund focused on the BDC sector, which has recently opened up to third party accredited investors. Prior to forming SCM, Mr. Marshi managed two private equity firms. Both firms were active in acquiring lower middle market private companies, principally in Southern California. Before getting into Private Equity, Mr Marshi was the head of the Los Angeles office of Kleinwort Benson Limited, a British merchant bank, from 1987-1990. Mr Marshi was involved in investment banking, lending and principal investing activities. At the outset of his career, Mr Marshi held various positions with Citibank at locations worldwide including Athens, Dubai, Puerto Rico and London. Mr Marshi is a graduate of Tufts University (B.A.) and Harvard University (M.A.).
I am a dividend investor and look for undervalued investments in the stock market. I identify misunderstood and undervalued equity investments and hold those securities until their price approximates my estimate of intrinsic value. I am a long-term investor only.
I am building a $100,000 high-yield income portfolio. I am running this portfolio as an experiment to see if long-term sustainable income can be generated from a diversified pool of high-risk, high-yield securities. I am willing to accept high risk in order to meet my performance goals.
Mark has been an investor for over 15 years, with a focus on income producing dividend and bond funds. He currently works in banking, and specializes in covering macro-economic trends and their impact on the major indices. Mark holds an undergraduate degree in Finance and an MBA. A former DI tennis player, Mark aspires to spend his days on the courts while his investments work for him.
I seek to liberate investors from the chains of borrowed opinions by teaching metric awareness that leads to the formation of your own opinions. I am a retail investor that gathers, processes and analyzes significantly more data than average. I share that data in my articles. I let the data do the talking. I am only taking dictation as the data tells its message.
Owner and operator of: www.biostockselite.com Have over 15 years of investment experience and interest is dedicated to small cap biotech stocks. Articles submitted to SeekingAlpha will also be posted to my aforementioned site.
Strategic investor/researcher with a primary focus in high percentage gain poised long equity investments. My research areas include the biotech/pharmaceutical sector, precious metals markets, short equities and natural resources.
Peter Geschek is a freelance writer, investor and the publisher of www.medfrontiers.com website. This is a site for medical innovation news and clinical trials news. Short, concise, important information about the latest is biotech and pharmaceuticals.
I was first interested in stocks and investing while in High School. With my first job I saved a significant portion of that and put it into various instruments i.e. Roth IRA and stocks mostly. I started college for Business Administration and continued teaching myself principles of investing and savings and good personal finance. I graduated with an MBA in Financial Planning from California Lutheran University in May of 2011.
I have not worked in any capacity as a financial analyst but have significant experience in stock analysis mainly using fundamental methods but have recently started using technical analysis as well. A significant portion of my free time is spent with this hobby and I have a lot at stake as I have been investing roughly 40% of my salary for the last 16 years. I have a significant nest egg at the moment and hope to be partially retired within 5 years by 2019. I have been building a property rental and investment business and continue to build that and expand that.
What does the future bring for me? I hope to continue building and growing my business as well as publish articles on investing and start a blog in the future as well.
I have a Bachelors Degree in Business Administration and have started up a website with the top 25 biotech stocks. I have been investing in biotech stocks for the last five years, and have done very well. My investing centers around being in long term in biotech stocks, because of the long term value potential. I like the risks in the biotech sector, along with the huge rewards.
Team StockMatusow.com research and writers are:
Scott Matusow; Team Leader, owner and founder of StockMatusow.com and Dan Cohen, partner, and independent investor/scientist/inventor/trader and lead contributor at stockmatusow.com.
Scott is an independent investor/writer/trader and team leader of StockMatusow.com.
He has have about 17 years of stock market experience which include trading, investing, and managing his family’s trust as well as his personal account.
Scott has had the most success in trading/investing in smaller cap growth companies. Because Scott is not 'officially trained' in the markets, he see things outside the box, using his experience to provide clarity and alpha. Scott uses his ability to read situations, emotion, charts, times and sales, historical data, and macroeconomic and other market forces to predict stock price movements, in both short and longer terms situations.. Using these acquired allowed for him to completely divest his own and family's money near the top of the market before the 2008 financial crisis.
Dan Cohen is a partner at stockmatusow and entrepreneur in the fields of nanotechnology, medical diagnostics, and energy storage. Additionally, Dan is a Scientist and inventor. He has 7 years of experience investing and trading biotechnology focused equities with a specialty in identifying under-appreciated value in small caps. Dan utilizes his experience reading and reviewing scientific literature to evaluate prospects for success. His work with diagnostics development give him a strong background in immunology which is leveraged in evaluating immunoncology focused approaches. As well Dan has 5 years trading futures, specializing in E-minis and Treasury products. He utilizes a combination of technical analysis, deep scientific research, and macro views to generate alpha for the team.
Places you can follow Scott are:
Places to follow Dan are:
Sy Harding founded Asset Management Research Corporation in 1988 for the purpose of providing stock market and economic research to institutions and serious investors. Harding’s engineering background, coupled with his experience in operating high-tech businesses through numerous economic cycles, made it natural that the research involves technical analysis and charting, as well as analysis of the economic fundamentals that affect markets and individual stocks.
The firm publishes its research on its website at www.StreetSmartReport.com.
Harding is frequently ranked highly in the ‘Top Ten Market Timers in the U.S.’, and is quoted frequently in the financial media.
He wrote the timely 1999 book Riding the Bear – How to Prosper in the Coming Bear Market, which accurately predicted the 2000-2002 bear market. It also introduced Sy’s remarkable Seasonal Timing Strategy, which more than doubled the performance of the S&P 500 and Nasdaq in the nine years since, without a single down year even in the serious 2000-2002 bear market.
He has a new book out ‘How to Beat the Market the Easy Way’, which reveals several new seasonal timing strategies, from short-term to long-term, which have a history of out-performing the market, while exposing investors to less than 50% of market risk.
Zman, is an investor/trader who specializes in the energy sector. He has managed small cap growth portfolios, been an energy banker, and a sell side exploration and production analyst (Prudential and Jefferies) in his 20 years in the financial markets. His daily writeups address developments in that sector and the potential impact on publicly traded stocks, options, and futures.
Visit his site: Z4 Energy Research http://www.zmansenergybrain.com
Follow our tweets at ZmansEnrgyBrain
A full time investor in stocks, bonds, options, and real estate who previously worked as a financial/investment journalist/analyst. Previous industry stints include privately held SageOnline Inc. - where he held multiple positions - as well as Multex.com, acquired by Reuters, where he was an equity research editor. Aloisi is a cum laude graduate of Penn State University, currently residing in native South Central Pennsylvania with his wife and 2 children.
Income investing has become his focal interest due to the challenges that the ZIRP environment presents. Not an advocate of any single portfolio strategy, he promotes a "go anywhere" philosophy predicated on value, forward thinking, sustainability, and personal objectives. While the past may be instructive, Aloisi cautions on over reliance.
In his free time he likes to talk politics, play the piano, garden, and go antiquing. Mr. Aloisi voluntarily serves as VP of his local school board.
Donald R. van Deventer founded the Kamakura Corporation in April, 1990 and is currently Chairman and Chief Executive Officer. Dr. van Deventer's emphasis at Kamakura Corporation is enterprise wide risk management and modern credit risk technology. The second edition of his newest book, Advanced Financial Risk Management (with Kenji Imai and Mark Mesler) was published in 2013 by John Wiley & Sons. In 2003 Dr. van Deventer co-authored Credit Risk Models and the Basel Accords with Kenji Imai. His second book, also with Kenji Imai, is Financial Risk Analytics: A Term Structure Model Approach for Banking, Insurance, and Investment Management published by Irwin in 1996. Dr. van Deventer's first book Financial Risk Management in Banking (with Dr. Dennis Uyemura, Probus Publishing, 1993) is one of the best known books in its field. He has served on the editorial board of the Journal of Credit Risk since 2005. Dr. van Deventer's primary financial consulting and research interests involve the practical application of leading edge financial theory to solve critical financial risk management problems. Dr. van Deventer has been involved in financial advisory assignments including both risk management and mergers and acquisitions. He has worked on assignments for the municipalities affected in the Orange County bankruptcy, in a major derivatives dispute between JPMorgan and a Korean securities firm, for Bank Negara Malaysia, the Department of the Treasury of the United States, governments of three of the OECD countries and many of the world’s largest financial institutions. Prior to founding Kamakura Corporation, Dr. van Deventer was senior vice president in the investment banking department of Lehman Brothers (then Shearson Lehman Hutton) from 1987 to 1990. During that time, he was responsible for 27 major client relationships including Sony, Canon, Fujitsu, NTT, Tokyo Electric Power Co., and most of Japan's leading banks. Dr. van Deventer completed three of the first four mergers and acquisitions assignments for a Japanese client by Lehman Brothers and the first domestic Japanese corporate straight bond underwriting by the firm. From 1982 to 1987, Dr. van Deventer was the treasurer for First Interstate Bancorp in Los Angeles. In this capacity he was responsible for all bond financing requirements, the company’s commercial paper program, and a multi-billion dollar derivatives hedging program for the company. During this time, First Interstate became the first issuer of medium term notes in the Euro market and first issuer of bank medium term notes. Dr. van Deventer also served as senior planning officer for acquisitions, new ventures and corporate strategy, participating in the 1986 attempted take-over of BankAmerica Corporation. Dr. van Deventer was a Vice President in the risk management department of Security Pacific National Bank from 1977 to 1982, where he initiated the duration-based futures hedging program for the bank. Dr. van Deventer holds a Ph.D. in Business Economics, a joint degree of the Harvard University Department of Economics and the Harvard Graduate School of Business Administration. He was appointed to the Harvard University Graduate School Alumni Association Council in 1999 and has now completed more than a decade of service on the Council. Dr. van Deventer served as Chairman of the Council for four years from 2012 to 2016. From 2005 through 2009, he served as one of two appointed directors of the Harvard Alumni Association representing the Graduate School of Arts and Sciences. Dr. van Deventer was named to the CFA Hawaii Advisory Board in 2010. Dr. van Deventer was also named to the Advisory Board of the Pacific Asian Center for Entrepreneurship and E-Business at the University of Hawaii Shidler College of Business in 2012. He served as a director of the Hawaii Bicycling League from 2005 to 2014. Dr. van Deventer also holds a degree in mathematics and economics from Occidental College, where he graduated second in his class, summa cum laude, and Phi Beta Kappa. Dr. van Deventer speaks Japanese and English.
Zacks.com brings the decades of study and stock picking expertise of Zacks Investment Research to individual investors. Now, you don't to be an investment bank or brokerage firm to get the professional power of Zacks' research. It's all available on Zacks.com. Learn more about Zacks' history and company below.
Individual investor focused upon a limited number of diversified stocks. Seeks stocks selling below fair value; favors dividend growth. Advocates fundamental investment analysis, supplemented by the technical charts. Options strategies primarily employed to generate additional income or hedge risk.